文献速递结核与非结核分枝杆菌

接受抗TNF-α治疗的儿童与青少年结核病:ptbnet多中心研究

Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

最常见的基础疾病为克罗恩病(8例,42%)和幼年特发性关节炎(6例,32%);所有病例均表现为重症,以粟粒性结核为主(14例,78%),且完成抗结核治疗的15例中有5例(33%)遗留长期后遗症。作者指出,该人群中潜伏性结核感染筛查常出现假阴性,建议在诊断免疫介导疾病时、开始免疫抑制治疗前即进行筛查。

要点

  • 抗TNF-α治疗期间发生结核病的儿童多表现为重症,以粟粒性结核为主。
  • 免疫抑制治疗可降低结核筛查试验的敏感性,筛查假阴性常见。
  • 建议在开始免疫抑制治疗前完成潜伏性结核感染筛查。

核心结论

  • 接受抗TNF-α治疗的儿童与青少年易发生重症结核病并遗留显著长期后遗症,需在该高危人群中建立可靠的潜伏性结核感染筛查方案,即使所在地区结核患病率较低。

研究设计与样本

  • 欧洲儿科结核病试验网络(ptbnet)内的回顾性多中心研究,纳入66家为结核病患儿提供诊疗的三级医疗机构,收集18岁以下、在接受抗TNF-α治疗期间发生结核病的患者。

主要发现

  • 15例在开始抗TNF-α治疗前接受了基于免疫的结核筛查(结核菌素皮肤试验和/或干扰素-γ释放试验),仅识别出1例潜伏性结核感染;13例筛查时已在接受免疫抑制治疗。
  • 从开始抗TNF-α治疗至结核诊断的中位间隔为13.1个月(IQR 7.1–20.3)。
  • 全部病例均表现为重症,以粟粒性结核为主(14例,78%);1例为死后诊断;15例(79%)经微生物学确诊。
  • 抗结核治疗中位疗程为50周(IQR 46–66);完成治疗的15例中5例(33%)遗留长期后遗症。

临床怎么用

  • 对患有免疫介导疾病的儿童,应在诊断时、开始免疫抑制药物之前进行潜伏性结核感染筛查。
  • 接受抗TNF-α治疗的儿童若出现重症结核表现,应考虑结核病可能并及时评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In adults, anti-tumor necrosis factor-α (TNF-α) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease, but pediatric data are limited. METHODS: Retrospective multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing patients <18 years who developed TB disease during anti-TNF-α therapy. RESULTS: Sixty-six tertiary healthcare institutions providing care for children with TB participated. Nineteen cases were identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin skin test and/or interferon-γ release assay) was performed in 15 patients before commencing anti-TNF-α therapy but only identified 1 LTBI case; 13 patients were already receiving immunosuppressants at the time of screening. The median interval between starting anti-TNF-α therapy and TB diagnosis was 13.1 (IQR, 7.1-20.3) months. All cases presented with severe disease, predominantly miliary TB (n = 14; 78%). One case was diagnosed postmortem. TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB treatment was 50 (IQR, 46-66) weeks. Five of 15 (33%) cases who had completed TB treatment had long-term sequelae. CONCLUSIONS: LTBI screening is frequently false-negative in this patient population, likely due to immunosuppressants impairing test performance. Therefore, patients with immune-mediated diseases should be screened for LTBI at the point of diagnosis, before commencing immunosuppressive medication. Children on anti-TNF-α therapy are prone to severe TB disease and significant long-term morbidity. Those observations underscore the need for robust LTBI screening programs in this high-risk patient population, even in low-TB-prevalence settings.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Noguera-Julian A, Calzada-Hernández J, Brinkmann F, et al. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. Clin Infect Dis. 2020. PMID: 31796965. doi:10.1093/cid/ciz1138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。